DongKoo Bio’s First Half Sales Soaring to 96 Billion Won and Operating Profit 10.2 Billion Won, “Record Earnings”

DongKoo Bio & Pharma announced on August 17 that its first half operating profit was 10.2 billion won, which increased year-on-year by 180%.

The sales during the same period increased by 29%, recording 96 billion won.

The company explained regarding its first half performance, “It is thanks to uniform growth in all business areas.

In addition to dermatology that has maintained the top prescription positon for several years, and urology that has been on the rise, internal medicine and otolaryngology, which have been recently intensively pushed on, have driven earnings growth in line with the expanding demand due to the coronavirus.

It added, “The sales of Dermotasone MLE and Uropa sustained release tablet in dermatology and urology areas have improved, and Gliforce soft capsule and Allestin tablet in internal medicine and otolaryngology areas have grown.”

An official from the company said, “In the overseas business sector, sales in Taiwan and other countries have expanded thanks to the sale of Covid-19 diagnostic kits, and we expect overseas sales of quasi-drugs as well as existing drugs to expand. In R&D, common bioequivalence sales have increased through excellent development capability.”

[WIKI KOREA=Cho Pil Hyun, Staff Reporter]